[ad_1]
A Text of Alain Labelle
The present works published in the medical journal The Lancet (in English) showed that this experimental vaccine against HIV-1 was well tolerated and generated good immune responses in 393 healthy adults aged 18 to 50 from Africa, Thailand, and the US
Treatment also produced an anti-HIV immune response in monkeys rhesus.
Further tests are in progress to determine whether the immune response produced is sufficient to prevent HIV infection.
These results represent an important step towards the creation of a vaccine.
Did you know?
Currently, 37 million people live with HIV / AIDS on the planet. No less than 1.8 million new cases were diagnosed in 2016.
A virus difficult to define
Despite the many advances in treatment, there is still no cure for HIV. The development of a preventative vaccine could, according to the researchers, lead to its eradication.
This vaccine is one of five experimental concepts of HIV-1 vaccines that have led to efficacy trials. in humans since the onset of the pandemic 35 years ago
Previous HIV vaccines have been tested in specific regions of the world
In this study, researcher Dan Barouch of the Harvard Medical School, and colleagues from several educational institutions around the world, took pieces of different strains of HIV and combined them to trigger immune responses against a wide variety of strains. of HIV
The goal was to define the optimal dosage to proceed to clinical efficacy trials
These results should be interpreted with caution
Source link
